Among cancer immunotherapies, the most common are interleukin, tumor vaccines and ICls such as death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors as well as Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) cell therapy. This evidence concerns the gene CTLA4 and neoplasm.